DALI LDL-Apheresis: Anticoagulation with R-Hirudin in a Patient with Heparin-Induced Thrombocytopenia (HIT II)

Abstract

A 50-year old male patient with familial hypercholesterolemia and hyperlipoproteinemia (a), who underwent low density lipoprotein-apheresis treatment developed heparin-induced thrombocytopenia type II (HIT II). Because heparin is contraindicated in patients with HIT, an alternative LDL-apheresis system and modified anticoagulation regimen was necessary. Treatment was changed to a new system called DALI (direct adsorption of lipids). After confirmation of the diagnosis HIT II, DALI LDL-apheresis was carried out with recombinant-hirudin (lepirudin) and citrate in order to prevent hypercoagulability. Efficient LDL-apheresis therapy with minimum therapeutic blood levels of lepirudin (1.4 mg/dl) was achieved with an initial intravenous bolus of 0.114 mg/kg of lepirudin followed by continuous lepirudin infusion of 0.350 mg/h. Thrombin-antithrombin III complex production was well controlled and other hemostatic markers showed no abnormalities. LDL-cholesterol and lipoprotein(a) concentrations were effectively reduced. R-hirudin offers a novel anticoagulation strategy and is, at present, the only alternative for patients with HIT II requiring LDL-apheresis on a regular basis.

Keywords

Anticoagulation DALI Heparin-induced thrombocytopenia hirudin LDL-apheresis therapy

Get full access to this article

View all access options for this article.

References

Schuff-Werner

, Gohlke

, Bartmann

. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest 1994; 24: 724–32.

Dräger

U.J.

, Kraenzle

, Schaper

. DALI- the first whole blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998; 28: 994–1002.

Warkentin

T.E.

. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Safety 1997; 17: 325–41.

Alving

B.M.

, Krishnamurti

. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin Thromb Hemost 1997; 23: 569–74.

Kelton

J.G.

, Warkentin

T.E.

. Heparin-induced thrombocytopeniadiagnosis, natural history, and treatment options. Postgraduate Medicine 1998; 103: 169–78.

Schmidt

O.H.

, Lang

. Heparin-induced thrombocytopenia with thromboembolic arterial occlusion treated with recombinant hirudin. NEJM 1997; 337: 1389.

Greinacher

, Amiral

, Dummel

, Vissac

, Kiefel

, Mueller-Eckhardt

. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet aggregation test and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34: 381–5.

Nowak

, Bucha

, Brauns

, Czerwinski

. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997; 23: 109: 354–8.

Nowak

, Bucha

. Quantitative determination of hirudin in blood and body fluids. Sem Thromb 1996; 22: 197–202.

10.

Nand

, Wong

, Yuen

, Yetter

, Schmulbach

, Gross Fisher

. Heparin induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56: 12–6.

11.

Warkentin

T.E.

. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effect on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG (Abstract). Blood 1996; 88(suppl): S626a.